Drug Trial Radar · NCT06101095
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
69
Actual
Start
Nov 29, 2023
Primary completion
Nov 5, 2025
Study completion Feb 1, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Oct 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) * Screening period: Up to 12 weeks before Week 0 * Randomized double-blind period: 24 weeks * Open label period: 104 weeks * Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first. There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).
Conditions
- Eosinophilic Oesophagitis
Interventions
DupilumabDrug
Subcutaneous injection (SC) as per protocol
PlaceboDrug
SC injection as per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)Time frame: From baseline to Week 24
Locations
30 sites in 5 countries. Site status is shown where the registry gives one.
United Gastroenterologists - Murrieta- Site Number : 8400001
Murrieta, California
University of California San Francisco - Parnassus Heights- Site Number : 8400020
San Francisco, California
Borland Groover Clinic- Site Number : 8400016
Jacksonville, Florida
Treasure Valley Medical Research- Site Number : 8400018
Boise, Idaho
Northwestern University- Site Number : 8400003
Chicago, Illinois
GI Alliance - Glenview- Site Number : 8400012
Glenview, Illinois
Illinois Gastroenterology Group- Site Number : 8400004
Gurnee, Illinois
University of Iowa- Site Number : 8400006
Iowa City, Iowa
University of Massachusetts Chan Medical School- Site Number : 8400019
Worcester, Massachusetts
Mayo Clinic Hospital Rochester- Site Number : 8400008
Rochester, Minnesota
University of North Carolina at Chapel Hill- Site Number : 8400007
Chapel Hill, North Carolina
Cleveland Clinic - Cleveland- Site Number : 8400009
Cleveland, Ohio
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010
Philadelphia, Pennsylvania
Private Practice - Dr. Martin Yudovich- Site Number : 8400015
Houston, Texas
GI Alliance - Mansfield- Site Number : 8400017
Mansfield, Texas
Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760003
São Paulo, Brazil
Itaigara Memorial - Hospital Dia- Site Number : 0760005
Salvador, Estado de Bahia, Brazil
Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006
Porto Alegre, Rio Grande do Sul, Brazil
Clínica Loema - Unidade I- Site Number : 0760007
Campinas, São Paulo, Brazil
Clinica de Alergia Martti Antila- Site Number : 0760001
Sorocaba, São Paulo, Brazil
Investigational Site Number : 1240006
Vancouver, British Columbia, Canada
Investigational Site Number : 1240004
Vancouver, British Columbia, Canada
Investigational Site Number : 1240002
Montreal, Quebec, Canada
Investigational Site Number : 3760006
Haifa, Israel
Investigational Site Number : 3760002
Haifa, Israel
Investigational Site Number : 3760005
Jerusalem, Israel
Investigational Site Number : 3760004
Jerusalem, Israel
Investigational Site Number : 3760003
Tel Aviv, Israel
Investigational Site Number : 7560001
Wetzikon, Switzerland
Investigational Site Number : 7560002
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.